ciprofloxacin + cotrimoxazole + nitrofurantoin

This entry describes a hypothetical combination of three distinct antibacterial agents: ciprofloxacin, cotrimoxazole (a fixed-dose combination of sulfamethoxazole and trimethoprim), and nitrofurantoin. Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, crucial enzymes for bacterial DNA replication and repair, leading to bacterial cell death. Cotrimoxazole acts by blocking two sequential steps in the bacterial folic acid synthesis pathway: sulfamethoxazole inhibits dihydropteroate synthase, and trimethoprim inhibits dihydrofolate reductase, thereby preventing the synthesis of nucleic acids and proteins essential for bacterial growth. Nitrofurantoin is a nitrofuran class antibacterial that, once activated by bacterial enzymes, produces highly reactive intermediates that damage bacterial DNA, ribosomal proteins, and other metabolic enzymes. While each drug is individually approved and widely used for various bacterial infections, particularly urinary tract infections, this specific three-drug combination is not a formally developed or marketed single product. Such a combination might be considered in complex clinical scenarios requiring broad-spectrum coverage or to overcome resistance, but it would involve co-administering the individual medications.

Brand names

CiproBactrimSeptraMacrodantinMacrobid

Other names

ciprofloxacin, cotrimoxazole, nitrofurantoin-University of British Columbia-kidney stonestrimethoprim-sulfamethoxazoleciprofloxacin + trimethoprim-sulfamethoxazole + nitrofurantoin